Clexane

DRUG3 trials

Sponsors

Melbourne Health, Rovi Pharmaceuticals Laboratories, PharmaDiall Ltd.

Conditions

COVID-19Deep Vein ThrombosisHealthyVenous Thromboembolism

Phase 1

Study of Pharmacodynamic Equivalence of Enoxaparin Rovi to Clexane®, in Healthy Volunteers

CompletedNCT03363477

Rovi Pharmaceuticals LaboratoriesHealthy

Start: 2015-09-25End: 2015-12-01Updated: 2017-12-06

Phase 3

Clinical Trial of Dimolegin (DD217) in Prevention of Thrombotic Complications in Patients With COVID-19

CompletedNCT05185804

PharmaDiall Ltd.COVID-19, Venous Thromboembolism

Start: 2021-02-08End: 2021-10-29Updated: 2022-01-11

Phase 4

The Effect of Enoxaparin Sodium on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.

TerminatedNCT00232271

Melbourne HealthDeep Vein Thrombosis

Start: 2005-08-31End: 2011-02-28Updated: 2013-05-30

Related Papers

Efficacy and Safety of a New Selective Oral Factor Xa Inhibitor Amidine Hydrochloride for Prevention of Thromboembolic Events in Hospitalized Patients with COVID-19: a Multiple-Center Prospective Randomized Controlled Study

Journal of Venous Disorders2024-06-171 citations